Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an update.
Hansoh Pharmaceutical Group Company Limited has scheduled a board meeting for March 29, 2026 to review and approve the audited final results of the company and its subsidiaries for the financial year ended December 31, 2025. The board will also consider recommending a final dividend, if any, and may address other corporate matters, signaling upcoming disclosures that could influence shareholder returns and market perceptions of the group’s performance.
The meeting date announcement provides investors with a timeline for when detailed financial information and potential dividend decisions will be made public. It also underscores the company’s adherence to corporate governance procedures through formal board deliberation on results and capital allocation, which are key to assessing management execution and future strategy.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$44.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a Hong Kong-listed pharmaceutical company incorporated in the Cayman Islands and traded under stock code 3692. The company operates through a board led by chairlady and executive director Zhong Huijuan, supported by additional executive and independent non-executive directors overseeing its governance and strategic decisions.
Average Trading Volume: 8,103,515
Technical Sentiment Signal: Buy
Current Market Cap: HK$198.7B
See more data about 3692 stock on TipRanks’ Stock Analysis page.